Zai Lab has a broad and validated late-stage pipeline in oncology and infectious disease. We currently have 2 products commercialized and 3 drugs approved in the U.S. Overall, our pipeline consists of over 15 drug candidates with over 20 ongoing or planned clinical trials.
Drug
Indication
Topic
ZL-2306 (Niraparib)
Ovarian Cancer
To evaluate the efficacy and safety of ZL-2306 for maintenance treatment of platinum-sensitive recurrent ovarian cancer
ZL-2306 (Niraparib)
Ovarian Cancer
To evaluate the efficacy and safety of ZL-2306 for maintenance treatment of ovarian cancer patients who were responsive to first-line chemotherapy
ZL-2306 (Niraparib)
Small Cell Lung Cancer
To evaluate the efficacy and safety of ZL-2306 for maintenance treatment of ED-SCLC patients after first-line chemotherapy
FPA-144
Gastric Cancer & Gastroesophageal Cancer
Evaluation of I/III randomized controlled trial of FPA144 combined with FOLFOX6 in the treatment of advanced gastric cancer
ZL-2301 (Brivanib)
Hepatocellular Carcinoma
The efficacy, safety and pharmacokinetics of ZL-2301 in advanced liver cancer
For more information about the above trials, please visit http://www.chinadrugtrials.org.cn/